Skip to content

Epidaurus · Treatment Guide · Alternative & Complementary Medicine

Going abroad for —

Hyperthermia Treatment

Hyperthermia and other alternative cancer modalities

The country comparison

Which countries are best for hyperthermia treatment

The destinations ranked high→low under this lens — each with the reasoning behind its score, the cited evidence one click down, and its full report. The verdict is free; the report is the depth.

19 / 19 Countries ranked

Researched and assessed by the Epidaurus editorial pipeline against our published scale. A country below the rule is not yet assessed enough — never ranked last.

  1. 1 Germany DE 5.0/5 Good Germany unambiguously meets all Score 5 criteria across every dimension. It operates 14+ ESHO-compliant facilities distributed across 9+ cities with all major hyperthermia modalities (local, regional deep, whole-body,... Full report
    The evidence behind this score 12 cited points
    • 14+ established hyperthermia facilities across 9 German cities with 9 ESHO-registered academic centers
    • All major hyperthermia modalities available: local, regional deep, whole-body, surface, MRI-guided (Tübingen—unique in Baden-Württemberg), and HIPEC, all CE-marked
    • EORTC 62961-ESHO 95 Phase III RCT published in JAMA Oncology 2018: 62.7% versus 51.3% 5-year overall survival for soft tissue sarcoma with chemo+hyperthermia versus chemo alone; 6 of 9 centers located in Germany
    • LMU Klinikum Munich: over 15,000 hyperthermia treatments administered; serves as coordinating center for landmark Phase III trial
    • Board-certified oncologists and radiation oncologists with specialized hyperthermia training; medical physicists required at all ESHO-compliant centers; IAH working group embedded in German Cancer Society
    • Hyperthermia fully legal and explicitly regulated by German Cancer Society (Deutsche Krebsgesellschaft) through IAH professional working group with published quality standards
    • Insurance coverage: GKV (statutory health insurance) covers inpatient hyperthermia at ESHO-compliant centers; PKV (private insurance) covers under GOÄ section 5854
    • Medical tourism infrastructure: Hyperthermia Centre Hannover (7 languages, established 1982), Hallwang Clinic (targeting US/UK/Australia/Middle East), Booking Health (ISO 9001 certified), published pricing €3,000–6,000 per week
    • Cost savings: 40–60% compared to equivalent hyperthermia treatment in United States at private clinics
    • Active clinical trials: NCT03249519 at Erlangen (cervical cancer with hyperthermia), THE001 Phase I at Munich (thermosensitive drug+hyperthermia for sarcoma)
    • Safety record: No significant adverse events; standard monitoring protocols at ESHO-compliant centers; mild side effects (sweating, transient reddening) only
    • Geographic distribution ensures broad access: facilities in Berlin, Düsseldorf, Erlangen, Essen, Lübeck, Munich, Nuremberg, Oberaudorf, Tübingen, and several private centers

    Read the full Germany report →

  2. 2 Japan JP 5.0/5 Good Japan meets or exceeds all Score 5 criteria: 25+ JSTM-certified hyperthermia facilities nationally distributed (well above 10+ requirement); MHLW-approved modern RF and microwave equipment since 1984; board-certified ... Full report
    The evidence behind this score 10 cited points
    • 25+ JSTM-certified facilities distributed from Hokkaido to Fukuoka, including Nagoya Kyoritsu, Omotesando AMC, Saito Yukoukai, and others
    • Thermotron RF-8 (8 MHz RF capacitive) MHLW-approved since 1984; CC-800 microwave device; modulated electro-hyperthermia at University of Toyama
    • Board-certified radiation oncologists and medical physicists integral to treatment teams; JSTM facility certification requiring defined training and clinical volume
    • National health insurance (NHI) covers hyperthermia for Japanese residents; Class II/III medical device regulation by PMDA
    • 5-year local control rate 97.7% in soft tissue sarcoma; 86% complete response with hyperthermia + radiotherapy; 29.5% malignancy regression in far-advanced cancers
    • Nagoya Kyoritsu Hospital opened International Medical Section (May 2023) with five-language support and JMIP accreditation; Omotesando AMC provides English services
    • Self-pay cost approximately ¥33,000 (USD 210) per session at private clinics; 2-month course ¥90,000 (USD 580) — 42–55% savings vs. US (USD 15,000–30,000)
    • No regulatory actions, facility closures, or serious adverse events; treatment-related adverse events monitored through JSTM certification
    • Co-edits International Journal of Hyperthermia with ESHO; Phase II clinical trial results published February 2025; active 43rd Annual Meeting 2026
    • Broad geographic distribution with multiple modalities (local, regional, whole-body); extensive documented treatment volume (e.g., Saito Yukoukai: 1,534 treatments 2020–2022)

    Read the full Japan report →

  3. 3 Poland PL 4.0/5 Good Poland qualifies as a Good (Score 4) destination for hyperthermia treatment. The country operates approximately 17 hyperthermia facilities including major academic oncology centers (NIO Warsaw with three dedicated dev... Full report
    The evidence behind this score 10 cited points
    • Approximately 17 hyperthermia facilities across Poland with geographic distribution in Warsaw, Poznań, Kraków, Katowice, Białystok, Kielce, and Rybnik
    • NIO Warsaw operates three dedicated hyperthermia devices, described as unique in Poland and rare in Europe; operational since 1989 with published research
    • CE-approved modern equipment from Celsius42 GmbH and Pyrexar Medical at major academic centers; multiple modalities available (local, regional, whole-body)
    • Board-certified radiation oncologists and clinical oncologists administer treatments; Polish Society for Oncological Hyperthermia published evidence-based recommendations covering 12 cancer indications
    • Hyperthermia fully legal under EU Medical Device Regulation; ESMO accreditation at NIO Warsaw (2023-2025); all six major Polish oncology societies recognize legitimate hyperthermia at accredited centers
    • NIO Warsaw participates in HEAT Phase III clinical trial; Gliwice NIO participated in European 16-center patterns-of-care analysis
    • Poland hosted ESHO 2019 (33rd Annual Meeting), Europe's premier hyperthermia oncology congress, confirming integration into international research community
    • Cost: 750 PLN (~€175) per session; full courses €1,400-€3,500 for complete treatment; represents 30-50% savings vs. Germany and larger savings vs. US
    • ECZ Otwock and KCM Clinic actively market to international patients with English-speaking staff and dedicated logistical support; Affidea MCO Poznań provides free accommodation
    • Key concern: Two-tier quality divide with some private commercial operators criticized by all six major Polish oncology societies for unproven claims and unvalidated adjunct procedures

    Read the full Poland report →

  4. 4 South Korea KR 4.0/5 Good South Korea operates one of the world's largest hyperthermia networks (60+ Oncotherm facilities, 11 BSD-2000 deep regional systems) across multiple cities with MFDS-approved, modern equipment. Published peer-reviewed ... Full report
    The evidence behind this score 11 cited points
    • 60+ hospitals and clinics registered with Oncotherm EHY devices distributed across Seoul, Busan, Daejeon, Gwangju, Jeonju, Incheon, Wonju, Daegu, Pohang, Ulsan, Cheonan, and Gyeonggi-do
    • Multiple hyperthermia modalities available: mEHT Oncothermia (EHY-2000plus, EHY-2030), Pyrexar BSD-2000 deep regional (11 units), Celsius42, and HIPEC at major academic centers
    • MFDS regulatory approval and CE-marked devices from registered distributors (Hospicare Co. Ltd. for Oncotherm, HanBeam Technology for Pyrexar)
    • JCI-accredited major university hospitals offering hyperthermia: Severance, Seoul National University Bundang, Samsung Medical Center, Asan Medical Center, Gachon University Gil, Korea University Anam
    • Published clinical outcomes: Wonju Severance 2022 trial (94% 5-year OS, 77.1% DFS in 60 locally advanced rectal cancer patients); Chonbuk 2017 study (50% vs 20% complete remission in cervical cancer)
    • Active clinical research: Yonsei Hyperthermia Study Group conducting NCT05282784 (flexible electrode 2-MHz device with radiotherapy)
    • Medical tourism infrastructure: South Korea surpassed 1 million international patients in 2024; major hospitals have dedicated English-speaking international patient coordinators
    • Cost savings of 30-50% vs US/Western Europe: local sessions USD 400-700, regional/deep USD 1,200-1,800, 2-week programs USD 10,000-15,000
    • No National Health Insurance coverage; hyperthermia not in NHIS benefit package, requiring all patients to pay out-of-pocket
    • Favorable safety profile with rare serious adverse events; minor side effects (erythema, hot sensation) in subset of patients
    • Korean Society for Thermal Medicine member of Asian Society for Hyperthermic Oncology (ASHO), linking practitioners to international hyperthermia community

    Read the full South Korea report →

  5. 5 Hungary HU 4.0/5 Good Hungary meets Score 4 criteria with 5-6 identified institutions offering CE-certified mEHT local/regional hyperthermia, qualified board-certified oncologists administering treatment at Semmelweis University, professio... Full report
    The evidence behind this score 10 cited points
    • Six Hungarian institutions designated as routine hyperthermia providers by SOSZK (Radiotherapy and Oncology Professional College) in 2005, with Semmelweis University confirmed as actively operating two CE-certified EHY-2000plus and EHY-2030 devices
    • Published clinical outcomes: cervical cancer showed 50% complete response rate with mEHT combined with chemoradiotherapy versus 15% with chemotherapy alone; brain tumour 5-year survival data published (83% astrocytoma, 3.5% glioblastoma)
    • Board-certified oncology team led by Prof. Magdolna Dank (Department Director) and Dr. Marcell Szász (MD, PhD, pathology board-certified, medical oncology fellowship), with multiple peer-reviewed publications in Frontiers in Oncology, Molecular Oncology, and PMC reviews
    • Active Phase II/III randomised clinical trial (NCT05889390) at Semmelweis University testing mEHT plus neoadjuvant chemotherapy in HER2-negative breast cancer (120 participants, estimated completion April 2025)
    • Approximately €5 million in government R&D funding from Hungarian NKFIH (National Research, Development and Innovation Office) to Semmelweis/Oncotherm consortium for device development and clinical research, 2016-2022
    • CE-certified Oncotherm mEHT equipment (modulated electro-hyperthermia at 13.56 MHz, capacitive radiofrequency technology) deployed at major facilities; Oncotherm has installed 550+ devices globally in 30+ countries
    • Whole-body hyperthermia is suspended domestically, limiting modality breadth compared to countries offering local, regional, and whole-body options
    • No published treatment packages or pricing for hyperthermia at Hungarian public hospitals; dedicated medical tourism infrastructure for hyperthermia specifically is absent following closure of the Kleef clinic (previously marketed to international cancer patients)
    • NEAK (national health insurance) reimbursement status unconfirmed despite SOSZK's 2005 advocacy for coverage following routine procedure designation
    • National Institute of Oncology Budapest holds OECI Comprehensive Cancer Center accreditation, the first such designation in Central and Eastern Europe, anchoring institutional credibility

    Read the full Hungary report →

  6. 6 Spain ES 4.0/5 Good Spain offers a solid mid-tier hyperthermia destination with 8–10 established facilities using modern CE-approved equipment across multiple modalities and cities, with formal regulatory recognition (OMC Nomenclátor 202... Full report
    The evidence behind this score 9 cited points
    • 8–10 established oncological hyperthermia facilities across multiple Spanish cities (Barcelona, Madrid, Málaga, Seville, Santander, Gran Canaria)
    • Multiple CE-marked/AEMPS-approved equipment modalities in use: CELSIUS42, Oncotherm EHY-2000, HY-DEEP 600WM, Pyrexar BSD systems
    • OMC Nomenclátor 2022 formal recognition of hyperthermia for 9+ cancer indications and AETSA positive health technology assessment
    • SEOR regulation requiring radiation oncologist oversight; Hospital Negrín peer-reviewed feasibility study (2019) with 86.8% protocol completion in 106 patients
    • Private insurance coverage through Quirónsalud/Teknon network with 8+ major Spanish insurers
    • Strong medical tourism infrastructure: Magna Clinic with hotel partnerships, Vithas Xanit (40% international patients, JCI-accredited), Centro Médico Teknon International Patients office
    • Cost structure €4,000–€10,000/week at Málaga clinics, representing 50–80% cost advantage versus US services
    • Spain hosted ESHO 36th Annual Congress in Málaga (November 2024), signaling integration into international hyperthermia research community
    • Multiple clinical trials: Hospital Marqués de Valdecilla Phase III trial and Teknon ongoing trials in prostate cancer re-irradiation with hyperthermia

    Read the full Spain report →

  7. 7 Mexico MX 3.0/5 Moderate Mexico offers accessible, affordable hyperthermia treatment through 5-7 established facilities concentrated in Tijuana with comprehensive medical tourism infrastructure and multiple treatment modalities. However, the ... Full report
    The evidence behind this score 10 cited points
    • 5-7 established hyperthermia facilities concentrated in Tijuana border region (Oasis of Hope, Immunity Therapy Center, Immunotherapy Institute, Hope4Cancer, Integrative Whole Health Clinic)
    • No published peer-reviewed clinical outcomes from Mexican hyperthermia facilities identified in research
    • Regulatory gray area: COFEPRIS oversight but Mexican drug regulation explicitly 'much looser than FDA' with no specific hyperthermia protocols identified
    • Documented safety concerns: contaminated homemade suppositories from a Hope4Cancer supplier arrested in Alabama netting $3.5 million
    • Equipment quality concerns: warning about some facilities using handheld radiofrequency devices that don't heat tumors properly
    • 50-70% cost savings compared to US treatment (exceeds Score 3 baseline of 20-40%)
    • Comprehensive medical tourism infrastructure: bilingual staff, airport pickup, accommodations, treatment packages ($5,000-$15,000 per cycle), multi-year follow-up
    • Multiple hyperthermia modalities available: whole-body, local/regional, perfusion hyperthermia with various technologies (RF, microwave, ultrasound, INDIBA)
    • Physicians include board-certified doctors (Dr. Contreras - oncologist/surgeon; Dr. Bautista with 30+ years alternative medicine), but no prominent mention of medical physicists
    • Positive but anecdotal patient testimonials; Oasis of Hope claims 100,000+ patients treated since 1963

    Read the full Mexico report →

  8. 8 Malaysia MY 3.0/5 Moderate Malaysia has an identifiable cluster of 3–4 private oncology facilities offering hyperthermia treatment, primarily superficial and deep local/regional modalities, at 70% cost savings versus US treatment. However, the ... Full report
    The evidence behind this score 10 cited points
    • 3–4 established facilities confirmed or listed (Parkway Cancer Centre, Dr Radzi Oncology, KPJ Ampang Puteri, Pantai Hospital) concentrated in Kuala Lumpur and Johor Bahru
    • Superficial microwave/RF and deep catheter-based hyperthermia confirmed; no whole-body or perfusion hyperthermia identified
    • MaHTAS published formal rapid review of hyperthermia device in 2022; hyperthermia legal in private sector but not formally approved in public hospital protocols
    • Dr Ahmad Radzi bin Ahmad Badruddin identified as dedicated hyperthermia specialist; no Malaysian practitioners identified as ESHO or Society for Thermal Medicine members
    • Zero peer-reviewed clinical outcomes publications from Malaysian hyperthermia facilities; reliance on international evidence (EORTC 62961–ESHO 95 trial)
    • Hyperthermia sessions cost USD 500–2,000, representing up to 70% savings versus US costs
    • JCI accreditation at KPJ Ampang Puteri and Pantai Hospital; English-language care standard; international patient services available
    • No documented adverse events or safety concerns; no regulatory actions against hyperthermia facilities
    • No specific insurance coverage for hyperthermia from major Malaysian insurers (Prudential, Allianz, Great Eastern)
    • Geographic distribution limited to capital/Klang Valley and southern region; no confirmed hyperthermia facilities in Penang or East Malaysia

    Read the full Malaysia report →

  9. 9 Israel IL 3.0/5 Moderate Israel merits a Moderate score for hyperthermia cancer treatment, anchored by a robust HIPEC network with 500+ procedures at JCI-accredited hospitals and world-class expertise (ICHS president based in Israel). However... Full report
    The evidence behind this score 10 cited points
    • 7+ identifiable hyperthermia facilities: New Hope Medical Center (Tel Aviv, dedicated clinic), Sheba Medical Center (500+ HIPEC procedures, JCI-accredited), Ichilov/Sourasky, Assuta, Hadassah, Rambam, Rabin Medical Center
    • International leadership: Dr. Joseph Brenner serves as President of International Clinical Hyperthermia Society; Dr. Almog Ben Yaacov at Sheba trained as one of world's first HIPEC specialists
    • Published peer-reviewed outcomes: 2025 case report in Frontiers in Oncology; 2024 case report in Gavin Publishers on magnetic nanoparticle hyperthermia; 15/28 Phase 1 trial patients achieved stable disease
    • JCI accreditation at Sheba, Ichilov, Rambam, and Hadassah hospitals
    • Cost savings: 35-50% at Assuta ($40,000) and Ichilov ($52,300) vs. U.S. HIPEC (~$80,000); some Sheba packages approach U.S. pricing ($61,200-$95,900)
    • World-leading innovation: New Phase magnetic nanoparticle hyperthermia at Rabin Medical Center (Phase 1 complete, FDA IDE approved, now installed at Mayo Clinic)
    • Comprehensive medical tourism infrastructure: dedicated International Medicine Departments, English-speaking staff, remote consultations available, Oncology Medical Tourism units
    • No safety incidents: No significant regulatory sanctions or Ministry of Health warnings identified; New Phase trial showed favorable safety profile
    • Equipment transparency gap: New Hope Medical Center does not disclose hyperthermia equipment manufacturer or model specifications
    • Geographic concentration: All hyperthermia services located in Tel Aviv metropolitan area, Haifa, or Jerusalem; no documented regional availability

    Read the full Israel report →

  10. 10 Thailand TH 3.0/5 Moderate Thailand offers moderate hyperthermia cancer treatment availability with 6+ identified facilities (Vejthani, Bumrungrad, Chiwamitra, and others), primarily concentrated in Bangkok but with some regional expansion. Maj... Full report
    The evidence behind this score 10 cited points
    • Six identified facilities offering hyperthermia: Vejthani International Hospital and Bumrungrad International Hospital (both JCI-accredited in Bangkok), Chiwamitra Cancer Hospital (Ubonratchatani), Panacee Medical Center, Hope4Cancer Thailand, and Verita Life Thailand
    • Multiple modalities available including local hyperthermia, regional hyperthermia, whole-body hyperthermia, HIPEC (Hyperthermic Intraperitoneal Chemotherapy), and Oncothermia technology
    • Cost: ฿200,000-฿400,000 Baht ($6,000-$12,000 USD) for 18-24 sessions representing 30-50% savings versus Western countries
    • Thai Ministry of Public Health drafting clinical oncology protocols mentioning hyperthermia as supportive treatment but explicitly described as 'still under pilot implementation'
    • Limited published outcomes: only one 2024 Thai systematic review on hyperthermia combined with radiation for advanced non-small cell lung cancer, with analysis hampered by 'limited resources' and concluding 'overall impact on survival uncertain'
    • No evidence of national health insurance or private insurance coverage for hyperthermia treatment; patients pay entirely out-of-pocket
    • Strong medical tourism infrastructure at JCI-accredited hospitals with multilingual staff, international patient coordinators, visa assistance, and accommodation support
    • Documented safety concerns at alternative cancer clinics: patient fatality at Verita Life Thailand (Julie Palmer case) with Australian oncologists finding cancer had exponentially progressed despite clinic assurances
    • Recent integration of hyperthermia into multidisciplinary tumor boards at major Bangkok and Chiang Mai hospitals indicating clinical acceptance but recent rather than established practice
    • Hyperthermia positioned primarily as complementary/alternative cancer treatment rather than integrated with mainstream conventional oncology protocols

    Read the full Thailand report →

  11. 11 Turkey TR 3.0/5 Moderate Turkey demonstrates moderate hyperthermia treatment availability with two established facilities (ChemoThermia and Medicana) using modern CE-approved OncoTherm equipment and publishing peer-reviewed clinical outcomes ... Full report
    The evidence behind this score 10 cited points
    • Two main hyperthermia facilities: ChemoThermia (dedicated center founded 2010) and Medicana Hospital network
    • OncoTherm EHY-3010 HT device (CE-approved, European manufacture) used for regional/whole-body hyperthermia
    • Services concentrated in Istanbul only; no documented hyperthermia availability in other Turkish cities
    • 88% complete response rate in pancreatic cancer patients with mean overall survival of 39.5 months (peer-reviewed publication)
    • Practitioners hold international credentials: ESMO, ASCO membership; Medicana certified by German Hyperthermia Society with Ruhr University collaboration
    • No explicit hyperthermia-specific regulatory approval by Turkish Ministry of Health; operates under general medical device regulation
    • HIPEC treatment cost $17,500-25,000 (30-35% cheaper than USA, Germany, Singapore)
    • Comprehensive medical tourism support: VIP transfers, English-speaking staff, treatment packages, medical visa assistance
    • No insurance coverage; hyperthermia offered as integrative/alternative modality rather than mainstream oncology integration
    • No significant adverse events reported; patients tolerated combined therapies well in published studies

    Read the full Turkey report →

  12. 12 Colombia CO 3.0/5 Moderate Colombia has four established HIPEC (perfusion hyperthermia) programs led by a flagship center (Fundación Santa Fe de Bogotá) with world-class outcomes (80% 10-year survival, <1% mortality, 1,000+ patients treated) an... Full report
    The evidence behind this score 8 cited points
    • Four HIPEC facilities identified: Fundación Santa Fe de Bogotá (flagship, 1,000+ patients), Instituto Nacional de Cancerología (150+ patients), Clínica Medellín, and Fundación Valle del Lili
    • FSFB achieves 80% 10-year overall survival with <1% mortality—described as 'comparable to first-world centers' in peer-reviewed Annals of Oncology publication
    • FSFB holds unique JCI certification specifically for peritoneal neoplasm management, reportedly the only such certification worldwide outside the United States
    • No evidence found of locoregional (RF/microwave), whole-body, or superficial hyperthermia equipment at any Colombian institution—modality limited to HIPEC perfusion
    • Colombia's overall cancer treatment costs run 50–80% below US levels; HIPEC treatment estimated $15,000–$30,000 vs. US price of $135,000–$150,000
    • Multidisciplinary integration at major centers with tumor board case review and published peer-reviewed outcomes from FSFB and INC in international journals
    • FSFB provides comprehensive international patient services with 24/7 bilingual support and Johns Hopkins collaboration, though HIPEC pricing not published
    • Newer facilities (Clínica Medellín since August 2023, Fundación Valle del Lili) lack published outcome data, limiting confidence for international patients

    Read the full Colombia report →

  13. 13 Singapore SG 3.0/5 Moderate Singapore offers hyperthermia treatment through JCI-accredited facilities with FRCR-qualified radiation oncologists and demonstrated research engagement, particularly in its HIPEC program (335+ procedures with 0% mort... Full report
    The evidence behind this score 8 cited points
    • External locoregional hyperthermia concentrated in Parkway Cancer Centre across 3 JCI-accredited hospital locations
    • No Singapore-specific published outcomes for external locoregional hyperthermia programs
    • NCCS HIPEC program demonstrates regional excellence with 335+ procedures, 0% mortality, 44.8% 5-year overall survival aligned with international benchmarks
    • Radiation oncologists hold FRCR credentials from Royal Marsden and St Bartholomew's Hospital with formal oncology training
    • High costs relative to regional medical tourism destinations (Thailand, Malaysia) with limited savings vs. Western countries
    • No confirmed insurance coverage for hyperthermia under MediShield Life or private plans
    • 12% of NCCS HIPEC patients are international self-referrals, demonstrating some medical tourism capacity
    • NCCS Division of Radiation Oncology published peer-reviewed review of locoregional hyperthermia in January 2023 (Cancers Basel)

    Read the full Singapore report →

  14. 14 United States US 3.0/5 Moderate The United States has excellent hyperthermia treatment quality with FDA-approved equipment, internationally recognized experts, and strong published outcomes, placing it above lower-scoring countries. However, it scor... Full report
    The evidence behind this score 9 cited points
    • Approximately 10-15 specialized facilities in major academic medical centers (UCSF, Duke, University of Maryland, Loyola Medicine, Temple, Washington University, Brown, Hyperthermia Cancer Institute, Maryland Proton Treatment Center)
    • FDA-approved modern equipment (BSD-2000, BSD-500) with state-of-the-art ultrasound, microwave, and RF technologies
    • Internationally recognized experts; UCSF led first North American phase III trial for hyperthermia+radiation; Duke received $19 million NCI grant
    • Excellent clinical outcomes: 83.7% tumor regression rate, 65% response rate for breast cancer with hyperthermia+radiation vs. 42% for radiation alone
    • Limited medical tourism viability: U.S. explicitly stated as source rather than destination country; Americans travel abroad for less expensive hyperthermia treatments
    • Costs $20,000-$50,000 per course with no cost savings vs. international alternatives; prohibitively expensive for international medical tourists
    • Medicare coverage restricted to local hyperthermia with radiation for superficial cancers only; regional deep tissue and whole-body hyperthermia considered investigational
    • Favorable safety profile with minimal complications reported; excellent adverse event monitoring systems
    • Strong regulatory approval via FDA Humanitarian Use Device for BSD-2000 for cervical cancer; legitimate treatment within mainstream oncology

    Read the full United States report →

  15. 15 India IN 2.5/5 Moderate India offers 3-4 established hyperthermia facilities with some internationally recognized ESHO-affiliated specialists and explicit regulatory framework under Medical Device Rules 2017, but falls between Poor and Moder... Full report
    The evidence behind this score 10 cited points
    • 3-4 established facilities identified: Tata Memorial Hospital, Regional Cancer Centre Thiruvananthapuram, HCG Oncology (Bangalore, Ahmedabad, Mumbai, Kolkata), Nanavati Hospital
    • Dr. Nagraj Huilgol serves on editorial boards of International Journal of Hyperthermia and European Society for Hyperthermic Oncology
    • Dr. Niloy Datta from India serves on ESHO Board, indicating international integration
    • Medical devices explicitly regulated under CDSCO Medical Device Rules 2017 (came into force January 2018)
    • Published clinical outcomes from Indian hyperthermia programs are remarkably scarce in publicly accessible sources
    • Hyperthermia-specific pricing completely opaque—facilities provide no transparency, listed as 'on request only'
    • Facilities treat hyperthermia as supportive therapy integrated with radiation/chemotherapy, not standard-of-care
    • India accepts 460,000+ foreign patients annually and ranks in TOP-5 for medical tourism, but hyperthermia-specific medical tourism pathways are underdeveloped
    • No insurance coverage identified for hyperthermia treatment in India
    • Treatment protocols documented (45-60 minute sessions, 2× weekly for 4-5 weeks) showing some standardization

    Read the full India report →

  16. 16 United Arab Emirates AE 2.0/5 Poor The UAE offers legitimate HIPEC (perfusion hyperthermia) at 5-7 JCI/ESMO-accredited hospitals with fellowship-trained surgical oncologists, but external local, regional, and whole-body hyperthermia modalities—the most... Full report
    The evidence behind this score 7 cited points
    • 5-7 documented HIPEC-offering hospitals at JCI/ESMO-accredited institutions (Cleveland Clinic Abu Dhabi, Burjeel Cancer Institute, American Hospital Dubai, Zulekha Hospital Dubai, Burjeel Specialty Hospital Sharjah)
    • Zero confirmed current external hyperthermia facilities; historical Thermotron equipment at Tawam Hospital and Gulf International Cancer Center (circa 2007) with no current confirmation
    • No explicit regulatory recognition or dedicated approval framework for hyperthermia as a treatment modality from UAE health authorities or Emirates Oncology Society
    • No published peer-reviewed clinical outcomes from UAE hyperthermia programs; UAE ranks 63rd globally in cancer research with 0.06% of world publications
    • UAE healthcare costs are premium (AED 40,000–120,000 for cancer treatment, ~USD 11,000–33,000), comparable to Western Europe, offering no cost savings advantage
    • MyMediTravel 2025 search for UAE hyperthermia clinics returned zero results, indicating UAE not recognized as hyperthermia medical tourism destination
    • Practitioners are fellowship-trained in surgical oncology with HIPEC expertise but no documented ESHO membership or external hyperthermia specialization

    Read the full United Arab Emirates report →

  17. 17 Brazil BR 2.0/5 Poor Brazil has a regulated, multi-center HIPEC program (11 SUS-authorized centers) with published clinical outcomes and formal regulatory approval via CONITEC and ANVISA registration, which exceeds a Score 1 assessment. H... Full report
    The evidence behind this score 8 cited points
    • 11 SUS-authorized HIPEC centers with regulatory approval via Ministerial Ordinance 1048 (May 2022)
    • Performer HT device ANVISA-registered (registration 10324290043); SBCO standardization guidelines published 2017
    • Published outcomes: 93.3% 2-year overall survival in multicenter phase 2 HIPEC trial for advanced ovarian cancer
    • HIPEC limited to rare peritoneal malignancies (PMP, MPM); loco-regional RF hyperthermia absent at mainstream hospitals
    • Zero presence on international medical tourism platforms (Bookimed.com does not list Brazil for HIPEC)
    • No published international patient packages, transparent pricing, or dedicated medical tourism coordinators for hyperthermia
    • Non-HIPEC facility (Instituto de Medicina Biológica) operated by nutrologists/homeopaths without oncology credentials or device registration; unverified 70-80% cure claims
    • INCA's official cancer treatment page omits hyperthermia; private insurance requires court litigation for coverage

    Read the full Brazil report →

  18. 18 United Kingdom GB 2.0/5 Poor The UK is not viable for hyperthermia medical tourism despite having excellent NHS HIPEC infrastructure (5-6 specialist centres, 3,000+ procedures at Basingstoke). The critical limitation is the complete absence of re... Full report
    The evidence behind this score 10 cited points
    • Complete absence of regional deep hyperthermia in routine UK clinical practice—the most commonly sought modality by medical tourists traveling to Germany, Netherlands, Austria
    • Superficial hyperthermia available only at Guy's Cancer Centre within a clinical trial (ThermoRad, NCT06659146), not as routine clinical service
    • Zero published medical tourism packages or pricing for international hyperthermia patients; no dedicated international patient coordinators
    • UK private healthcare costs among Europe's highest; no cost savings compared to hyperthermia reference countries
    • UK patients seeking locoregional hyperthermia are directed by UK healthcare advisors to travel to Germany—confirming outbound rather than inbound medical tourism flow
    • Private complementary clinics (Hightree Medical, Quantum Clinic, Hyperthermia Clinics International) practitioners lack radiation oncology training; Quantum Clinic explicitly states 'no claim can be made for cure or improvement'
    • 2022 systematic review found 'no evidence of survival benefit' for whole-body hyperthermia and modulated electro-hyperthermia (oncothermia)—the modalities offered by private clinics
    • NHS HIPEC centres excel in peritoneal cancer treatment (Christie: 86% 6-year survival for LAMN, 64% for malignant appendiceal tumours) but serve NHS referral pathways and do not market to international patients
    • NICE regulatory oversight applies narrowly: HIPEC fully approved, HIVEC approved under special arrangements, but regional deep hyperthermia has no NICE guidance or NHS commissioning
    • No insurance coverage for private hyperthermia; only NHS HIPEC covered for eligible UK patients

    Read the full United Kingdom report →

  19. 19 Jordan JO 1.0/5 Poor Jordan offers no documented oncological hyperthermia cancer treatment facilities. Comprehensive review of all four radiation oncology centers (KHCC, Al Basheer, Queen Alia, Al Afia) confirms none offer hyperthermia se... Full report
    The evidence behind this score 9 cited points
    • Zero oncological hyperthermia facilities — all four radiation oncology centers confirmed to offer only conventional radiotherapy modalities
    • JFDA has not registered any hyperthermia devices for oncological use in Jordan
    • Hyperthermia absent from Jordan's Unified National Cancer Treatment Protocol comprising 26 therapeutic guidelines
    • No Jordanian oncologists appear in ESHO (European Society for Hyperthermic Oncology) membership directories
    • Medical tourism platforms (CureMeAbroad, PlacidWay, Medigence) do not list hyperthermia as available in Jordan
    • No hyperthermia cancer treatment trials identified in ClinicalTrials.gov registry for Jordan
    • Jordan's 2025 Lancet Oncology 10-year national cancer strategy makes no mention of hyperthermia treatment introduction
    • KHCC departmental structure does not include a hyperthermia program despite being the region's foremost cancer center
    • Documented resource constraints (brain drain, equipment costs, training requirements) explain absence of advanced modalities like hyperthermia

    Read the full Jordan report →

Reading the field

What separates a good programme from a dangerous one

Every country above is graded against this published scale — the same 1–5 rubric for hyperthermia treatment, top to bottom. How we score →

  1. 5/5 Excellent

    **Criteria:** - 10+ established hyperthermia facilities offering treatment to international patients, distributed across multiple cities - Modern hyperthermia equipment (FDA/CE approved) with multiple modalities available (local, regional, whole-body) - Specialized hyperthermia-trained oncologists and medical physics support at major facilities - Hyperthermia fully approved and regulated by national health authorities as legitimate cancer treatment - Published clinical outcomes from in-country facilities showing efficacy comparable to international standards - Comprehensive medical tourism infrastructure: English-speaking staff, treatment packages, international patient coordinators, published pricing - Cost savings of 40-60% compared to US/Western Europe for equivalent hyperthermia treatment - Strong safety record with no significant adverse events or regulatory actions - Active participation in international hyperthermia research and clinical trials - Insurance coverage available (national or private) for hyperthermia treatment **Examples:** Germany, Netherlands, Japan, Austria, Czech Republic (if evidence supports this level)

  2. 4/5 Good

    **Criteria:** - 5-9 established hyperthermia facilities, possibly concentrated in 1-2 major cities - Modern hyperthermia equipment available, though perhaps fewer modalities than Score 5 countries - Qualified oncologists administering hyperthermia, with at least some specialized training - Hyperthermia legally approved for cancer treatment, with regulatory oversight in place - Some published outcomes or documented clinical experience, even if not extensive - Medical tourism services available: English communication possible, assistance with logistics, some international patients treated - Cost savings of 30-50% compared to US/Western Europe - Good safety record with appropriate adverse event monitoring - Some integration with conventional oncology (combined protocols) - Limited insurance coverage or approved for specific cancer types only **Examples:** Spain, Italy, Hungary, Poland, Turkey (if evidence supports this level)

  3. 3/5 Moderate

    **Criteria:** - 2-4 hyperthermia facilities, typically in capital/largest city only - Hyperthermia equipment present but may be older models or limited to one modality (e.g., only local hyperthermia) - Practitioners with general oncology training but limited specific hyperthermia specialization - Hyperthermia legal but may not be explicitly regulated or may be in regulatory gray area - Limited published outcomes; reliance on international evidence rather than in-country data - Basic medical tourism capability: some English communication, international patients accepted but limited specialized support - Cost savings present but less substantial (20-40% compared to US/Western Europe), or pricing not transparent - Adequate safety record but limited systematic monitoring or reporting - Hyperthermia offered more as alternative/complementary option than integrated with mainstream oncology - No insurance coverage; patients pay out-of-pocket **Examples:** Mexico, India, Thailand, Malaysia, Argentina (if evidence supports this level)

  4. 2/5 Poor

    **Criteria:** - Only 1 facility offering hyperthermia, or 2-3 very small/questionable operations - Outdated or unverified hyperthermia equipment; unclear if devices meet international safety standards - Practitioners without clear hyperthermia training; may be general alternative practitioners rather than oncologists - Unclear or questionable legal status; hyperthermia may operate in regulatory void or face restrictions - No published outcomes or clinical documentation available - Minimal medical tourism infrastructure: language barriers, no international patient support, unclear pricing - Cost may be low but quality concerns outweigh savings - Safety concerns: no systematic adverse event reporting, or some documented problems - Hyperthermia offered outside mainstream medical system, possibly in alternative clinics without oncology integration - No regulatory oversight or quality assurance mechanisms **Examples:** Countries with unregulated alternative cancer clinics offering hyperthermia

  5. 1/5 Very Poor / Unavailable

    **Criteria:** - No established hyperthermia cancer treatment facilities in the country, or only wellness/spa hyperthermia (not oncological) - Any existing hyperthermia may be illegal, prohibited, or strongly restricted by health authorities - No trained practitioners or appropriate medical equipment for therapeutic hyperthermia - No clinical evidence or outcomes data available - Not viable for medical tourism: no facilities accept international patients, no infrastructure, or unsafe conditions - Significant safety concerns or regulatory warnings about hyperthermia treatment **Examples:** Countries where hyperthermia is unavailable, prohibited, or only available in unsafe/unregulated settings

The reports

The full country reports under this lens

Each destination we have assessed has a full, cited report — the detailed analysis behind its score. The verdict is free; the report is the depth.

Clinics & providers

The clinics our research names

Named hospitals, clinics and centres cited across these findings — each carrying the specialties our reports record. Follow one to the reports behind it.

References

The sources behind these assessments

The distinct sources cited across these published reports — every finding carries its own citations; this is the union, each linking back to the reports that lean on it.

  1. Untitled source en.adipo.co.kr/bbs/board.php?bo_table=broadcast_e&wr_id=65 Cited in Hyperthermia Treatment in South Korea
  2. Untitled source keralahospitals.org/thiruvananthapuram/rcc-thiruvananthapuram Cited in Hyperthermia Treatment in India
  3. Untitled source www.snuh.org/global/en/about/EN05006003.do Cited in Hyperthermia Treatment in South Korea
  4. Untitled source absolutehealth.co.th/blog/hyperthermia Cited in Hyperthermia Treatment in Thailand
  5. Untitled source absolutehealth.co.th/hope4cancer Cited in Hyperthermia Treatment in Thailand
  6. Untitled source airomedical.com/destinations/country=turkey Cited in Hyperthermia Treatment in Turkey
  7. Untitled source app.trialscreen.org/trials/early-feasibility-to-evaluate-safety-recommended-dose-sarah-nanotechnology-trial-nct07224464 Cited in Hyperthermia Treatment in Israel
  8. Untitled source arogyajivan.com/oncology/cancer-therapies/hyperthermia-therapy-in-india-top-hospitals-and-treatment-costs Cited in Hyperthermia Treatment in India
  9. Untitled source asiaactual.com/india/medical-device-registration Cited in Hyperthermia Treatment in India
  10. Untitled source asiaactual.com/thailand-3/medical-device-registration Cited in Hyperthermia Treatment in Thailand
  11. Untitled source bangkokhealthservice.com/medical-tourism-part-4-what-treatments-and-surgeries-can-you-get-with-medical-tourism-in-thailand-and-what-do-they-cost Cited in Hyperthermia Treatment in Thailand
  12. Untitled source bimedis.com/celsius42-celsius-tcs-m53343 Cited in Hyperthermia Treatment in India
  13. Untitled source cancercenters.cancer.gov/cancer-centers/duke-cancer-institute Cited in Hyperthermia Treatment in United States
  14. Untitled source cancerworld.net/patients-in-turkey-sue-reimbursement-price-cancer-drugs Cited in Hyperthermia Treatment in Turkey
  15. Untitled source cdsco.gov.in/opencms/opencms/en/Medical-Device-Diagnostics Cited in Hyperthermia Treatment in India
  16. Untitled source cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2022/m_device/Medical%20Devices%20Rules,%202017.pdf Cited in Hyperthermia Treatment in India
  17. Untitled source cdscomdonline.gov.in Cited in Hyperthermia Treatment in India
  18. Untitled source chemothermia.com/about Cited in Hyperthermia Treatment in Turkey
  19. Untitled source corporate.dukehealth.org/news/feature-duke-physicians-turn-heat-tumors-hasten-their-demise Cited in Hyperthermia Treatment in United States
  20. Untitled source en.fda.moph.go.th Cited in Hyperthermia Treatment in Thailand
  21. Untitled source en.uniclinics.com/medical-tourism/turkey/oncological-treatment-in-turkey Cited in Hyperthermia Treatment in Turkey
  22. Untitled source en.wikipedia.org/wiki/Medical_tourism_in_South_Korea Cited in Hyperthermia Treatment in South Korea
  23. Untitled source en.wikipedia.org/wiki/Ministry_of_Food_and_Drug_Safety Cited in Hyperthermia Treatment in South Korea
  24. Untitled source en.wikipedia.org/wiki/Regional_Cancer_Centre,_Thiruvananthapuram Cited in Hyperthermia Treatment in India

Explore the source archive →

In plain language

Start exploring the knowledge base

The field's shorthand our reports use, sized by how often it comes up. Follow any term to its full entry and the reports that use it.

For readers weighing this decision

Ways to read the evidence

The verdict is always free. A membership opens the full analysis and every cited source — this specialty, the whole library, or everything for good.

  • One specialty · annual

    Alternative & Complementary Medicine

    $49.00 / year

    $49.00/year

    Every report in this specialty — full analysis and every cited source — as each is published.

    Take this specialty

  • Full library · annual

    The whole library

    $199.00 / year

    $199.00/year

    The complete evidence behind every finding in every specialty, while your decision is live.

    Take the full library
  • Most readers

    Lifetime · one payment

    Everything, for good

    $499.00 once

    $499.00 (one-time)

    Every finding we publish today and hereafter — no renewal, no expiry. The tier we point most readers to.

    Take lifetime access

Prefer to pay per report? A single report is $29.00, yours to keep — browse the reports. The verdict is always free.

Where to go from here · Hyperthermia Treatment

no scope is a dead end — step up to the specialty, drill into a factor, or pivot across to a country or a comparison